MiNK Therapeutics Undervalued Given Potential Of Platform

Dec. 05, 2022 10:43 PM ETMiNK Therapeutics, Inc. (INKT)AGEN4 Comments
William Meyers profile picture
William Meyers


  • MiNK Therapeutics reported positive results from two Phase 1 trials.
  • Invariant Natural Killer T cells offer advantages over standard therapies.
  • But it is a long road to the first FDA approval.

Natural killer cells attacking a cancer cell


MiNK Therapeutics (NASDAQ:INKT) is a clinical stage biotechnology company that was spun off from Agenus (AGEN), as a preclinical company, in October 2021. Its therapies are being developed using iNKT cells, or invariant natural

Data by YCharts

This article was written by

William Meyers profile picture
I provided stock and bond research and analysis to a small cap specialist investor, Lloyd Miller, from 2002 until his death in January 2018. For my own account I invest mainly in technology and biotechnology stocks. My technology and investment web site is openicon.com, where readers can view the notes I take to make decisions and to write articles for Seeking Alpha.

Disclosure: I/we have a beneficial long position in the shares of INKT, AGEN either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Recommended For You

Comments (4)

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.